Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Alpha1 Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy 1877-A

    Alpha1-Proteinase Inhibitors

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 1877-A alerts

    Get alerted when Policy 1877-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Aralast NP, Glassia, Prolastin-C, and Zemaira in adults with alpha1-antitrypsin deficiency and clinically evident emphysema. Coverage requires an approved indication and satisfaction of the specified serum AAT and post-bronchodilation FEV1 criteria.

    Policy Summary
    PayerBluecross Idaho
    PolicyAlpha1-Proteinase Inhibitors
    Policy CodePolicy 1877-A
    Change TypeNo material clinical or coverage changes
    Effective DateNot specified
    Next Review DateNot specified
    Key ActionObtain prior authorization and document clinically evident emphysema, serum AAT below 11 micromol/L, and post-bronchodilation FEV1 between 25% and 80% of predicted.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Covered products
    <11 micromol/LSerum AAT threshold
    25%-80%FEV1 range
    IndefiniteInitial authorization
    Not coveredOther indications
    Policy Summary
    PayerBluecross Idaho
    PolicyAlpha1-Proteinase Inhibitors
    Policy CodePolicy 1877-A
    Change TypeNo material clinical or coverage changes
    Effective DateNot specified
    Next Review DateNot specified
    Key ActionObtain prior authorization and document clinically evident emphysema, serum AAT below 11 micromol/L, and post-bronchodilation FEV1 between 25% and 80% of predicted.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundDefinitionsInitial TherapyContinuation Therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy

    Covered when all of the following criteria are met and the member has no exclusions to the prescribed therapy.

    Initial authorization requirements

    • Clinical disease: The member has clinically evident emphysema.
    • Serum AAT deficiency: The member's pretreatment serum AAT level is less than 11 micromol/L.<11 micromol/L; equivalent to 80 mg/dl by radial immunodiffusion or 50 mg/dl by nephelometry
    • Pulmonary function range: The member's pretreatment post-bronchodilation FEV1 is greater than or equal to 25% and less than or equal to 80% of predicted.>=25% and <=80% of predicted
    • Exclusions: The member has no exclusions to the prescribed therapy.

    Continuation Therapy

    Continuation therapy requires all initial authorization criteria.

    Continuation authorization

    • Initial criteria remain satisfied: The member has clinically evident emphysema.
    • Serum AAT deficiency: The member's pretreatment serum AAT level is less than 11 micromol/L.<11 micromol/L
    • Pulmonary function range: The member's pretreatment post-bronchodilation FEV1 is greater than or equal to 25% and less than or equal to 80% of predicted.>=25% and <=80% of predicted

    Not Covered Indications

    The following indications are not covered.

    Noncovered indications: All indications other than the specified FDA-approved indications for Aralast NP, Glassia, Prolastin-C, and Zemaira are considered experimental/investigational and are not a covered benefit.

    Coverage is available when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.

    Clinical Thresholds

    Pretreatment serum AAT level
    Required levelLess than 11 micromol/L
    Radial immunodiffusion equivalent80 mg/dl
    Nephelometry equivalent50 mg/dl
    Pretreatment post-bronchodilation FEV1
    Required rangeGreater than or equal to 25% and less than or equal to 80% of predicted
    Measurement timingPretreatment, after bronchodilation
    TestForced expiratory volume in 1 second (FEV1)

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Requirements

    Prior authorization is required for covered alpha1-proteinase inhibitor therapy. Initial approval may be granted for Aralast NP, Glassia, Prolastin-C, or Zemaira when the member meets all applicable clinical and laboratory criteria and has no exclusions to the prescribed therapy.

    • Covered FDA-approved use: chronic augmentation or maintenance therapy for adults with clinically evident emphysema due to severe congenital or hereditary alpha1-proteinase inhibitor (alpha1-antitrypsin) deficiency.
    • The member must have clinically evident emphysema.
    • The pretreatment serum AAT level must be less than 11 micromol/L, defined as 80 mg/dL by radial immunodiffusion or 50 mg/dL by nephelometry.
    • The pretreatment post-bronchodilation FEV1 must be at least 25% and no more than 80% of predicted.
    Prior Authorization

    Continuation Authorization Requirements

    Requests to continue alpha1-proteinase inhibitor therapy must satisfy all initial authorization criteria. This requirement applies to every member, including new members requesting authorization for therapy already in progress.

    Clinical Background

    Alpha1-proteinase inhibitors are used as chronic augmentation therapy in adults with severe hereditary or congenital alpha1-antitrypsin deficiency and clinically evident emphysema. Coverage is limited to members with a pretreatment serum AAT level of less than 11 micromol/L and moderate-to-severe airflow impairment, measured by a pretreatment post-bronchodilation FEV1 of 25% through 80% of predicted.

    Definitions

    Alpha1-antitrypsin deficiency
    ConditionA hereditary or congenital deficiency of alpha1-proteinase inhibitor, also called alpha1-antitrypsin deficiency
    Clinical associationAssociated with clinically evident emphysema
    Therapy contextThe deficiency is the condition treated by alpha1-proteinase inhibitor augmentation therapy
    Post-bronchodilation FEV1
    DefinitionForced expiratory volume in 1 second measured after administration of a bronchodilator
    ExpressionExpressed as a percentage of predicted
    Policy range

    Initial Therapy

    Initial Therapy

    Indefinite authorization may be granted when all of the following criteria are met.

    Initial therapy

    • Clinical disease: The member has clinically evident emphysema.
    • Serum AAT deficiency: The member's pretreatment serum AAT level is less than 11 micromol/L.<11 micromol/L; 80 mg/dl by radial immunodiffusion or 50 mg/dl by nephelometry
    • Pulmonary function range: The member's pretreatment post-bronchodilation forced expiratory volume in 1 second (FEV1) is greater than or equal to 25% and less than or equal to 80% of predicted.>=25% and <=80% of predicted

    Continuation Therapy

    Continuation Therapy

    All members, including new members, requesting continuation of therapy must meet all initial authorization criteria.

    Continuation therapy

    • Clinical disease: The member has clinically evident emphysema.
    • Serum AAT deficiency: The member's pretreatment serum AAT level is less than 11 micromol/L.<11 micromol/L
    • Pulmonary function range: The member's pretreatment post-bronchodilation FEV1 is greater than or equal to 25% and less than or equal to 80% of predicted.>=25% and <=80% of predicted
    • Continuation requests must document clinically evident emphysema.
    • Continuation requests must meet the serum AAT threshold and the pretreatment post-bronchodilation FEV1 range required for initial approval.
    • Authorization for continuation is subject to the applicable therapy exclusions.
    Documentation Required

    Clinical and Laboratory Documentation

    Submit clinical and laboratory documentation supporting the diagnosis and treatment criteria with the authorization request. Documentation must establish emphysema and include pretreatment AAT testing and pretreatment post-bronchodilation FEV1.

    • Document clinically evident emphysema.
    • Provide the pretreatment serum AAT level and testing method: radial immunodiffusion or nephelometry.
    • Document pretreatment post-bronchodilation FEV1 as a percentage of predicted; the qualifying range is 25% through 80% of predicted.
    Denial Risk

    Noncovered Indications

    Alpha1-proteinase inhibitor use for indications other than the specified FDA-approved indications is considered experimental/investigational and is not a covered benefit.

    • Covered FDA-approved products and uses are Aralast NP, Glassia, Prolastin-C, and Zemaira for chronic augmentation or maintenance therapy in adults with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema, as applicable to the product.
    • All other indications are noncovered.

    Unsupported block type: denial_risk

    Denial Risk

    Continuation Criteria Not Met

    A continuation request is at risk for denial if it does not satisfy all initial authorization criteria. This applies equally to established members and new members requesting authorization for ongoing therapy.

    • The request lacks documentation of clinically evident emphysema.
    • The serum AAT level or required testing documentation is missing or does not meet the initial threshold.
    • The pretreatment post-bronchodilation FEV1 documentation is missing or falls outside the 25%–80% predicted range.
    • Any applicable therapy exclusion or noncovered indication remains unresolved.
    Greater than or equal to 25% and less than or equal to 80% of predicted